Surgery Wasn't Enough. Now GLP-1s Are Entering the Picture for Adolescents.
A new CHLA study suggests GLP-1 medications may boost weight loss in teens who've already had bariatric surgery.
Now I have everything I need to write a well-sourced, compelling article. Let me put it together.
A study out of Children's Hospital Los Angeles just added a significant piece to one of pediatric medicine's trickiest puzzles: what do you do when bariatric surgery isn't enough?
Published this week via Newswise, the CHLA research found that GLP-1 medications may improve weight loss outcomes in adolescents who have already undergone bariatric surgery — a combination approach that, until recently, barely existed as a clinical conversation.
This matters. Not just for teens, but for anyone watching the GLP-1 landscape evolve in real time.
The Problem Surgery Alone Doesn't Always Solve
Bariatric surgery is the most effective intervention we currently have for severe adolescent obesity. But "most effective" doesn't mean permanent.
A 2022 review in Hormones Research in Paediatrics noted that long-term weight regain remains a significant challenge after adolescent bariatric procedures. A separate systematic review in Surgery for Obesity and Related Diseases found that while outcomes at five or more years post-surgery were generally positive, a meaningful subset of adolescents continued to struggle with weight maintenance over the long haul.
The CHLA study zeroes in on that gap — the teens who had surgery and still need more support.
What the CHLA Research Found
The Children's Hospital Los Angeles team looked at whether adding a GLP-1 receptor agonist after bariatric surgery could push outcomes further. Their findings, as reported by Newswise: GLP-1 medications may improve weight loss in adolescents who have already had bariatric surgery — suggesting a potential role for combination treatment in this age group.
The word "may" is doing important work in that headline. This is early-stage signal, not a mandate. But it's a signal worth taking seriously.
GLP-1s in Adolescents: What the Broader Evidence Says
This finding doesn't come out of nowhere. The evidence base for GLP-1 use in teens has been building steadily.
A meta-analysis published in JAMA Pediatrics in December 2025 reviewed the efficacy and safety of GLP-1 receptor agonists in children and adolescents with obesity or type 2 diabetes, finding support for their use in this population. An earlier network meta-analysis in Pharmaceuticals compared multiple GLP-1 agents in adolescents with obesity and found meaningful differences in both efficacy and tolerability across drugs.
On the regulatory side, the FDA's label for Wegovy (semaglutide) already includes an indication for pediatric patients aged 12 and older with obesity — making it one of the few GLP-1 drugs with an official adolescent approval. According to the FDA's Wegovy label, the most commonly reported adverse reactions in pediatric patients aged 12 and older include nausea, diarrhea, vomiting, constipation, and abdominal pain — the same GI profile seen in adults.
There's Already a Clinical Trial Asking This Exact Question
CHLA isn't alone in exploring this territory. ClinicalTrials.gov shows a completed Phase 2 trial (NCT04883346) that studied liraglutide in adolescents with obesity who were 1–10 years post sleeve gastrectomy and had a BMI of 30 or above. That trial, run out of the NIH, was designed specifically to test whether a GLP-1 drug could help teens who still had significant obesity after surgery.
The CHLA study appears to be building on exactly that foundation — and arriving at a similar conclusion from a real-world clinical lens.
Why This Combination Approach Is a Big Deal
For a long time, bariatric surgery and GLP-1 medications were treated as either/or options. Surgery for the most severe cases; medication for everyone else.
The CHLA findings push back on that framing. They suggest these tools might work better together — at least for some adolescents — rather than in sequence or competition.
A 2026 study in JAMA Network Open examined body composition changes after bariatric surgery versus GLP-1 receptor agonist treatment in adults, finding distinct differences in how each approach affects fat and lean mass. If those differences hold in adolescents, combining them could theoretically address different physiological mechanisms at once — though that hypothesis still needs direct testing in teens.
MedlinePlus notes that childhood obesity is a complex condition where weight and height must be evaluated relative to age and developmental stage — a reminder that adolescent care requires a different calculus than adult treatment.
What This Means for You
- If you're a parent or teen navigating post-bariatric weight regain, this research is worth bringing to your care team. It's not a green light — it's a conversation starter.
- The FDA has already approved semaglutide (Wegovy) for adolescents 12+, which means the regulatory path for this combination already exists; the clinical protocols are what's still catching up.
- This is early evidence, not a clinical standard yet. More trials and longer follow-up data are needed before combination therapy becomes routine practice in pediatric bariatric care.
Not medical advice. Talk to your prescriber or your child's care team about your specific situation.
